{
    "clinical_study": {
        "@rank": "122527", 
        "arm_group": [
            {
                "arm_group_label": "BIIB037", 
                "arm_group_type": "Experimental", 
                "description": "Administered by intravenous (IV) infusion"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Administered by intravenous (IV) infusion"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and tolerability of multiple doses of\n      BIIB037 administered via intravenous (IV) infusions in subjects with prodromal or mild\n      Alzheimer's Disease (AD). Patients who meet the inclusion criteria will be eligible for a\n      dose-blinded long-term extension (LTE), following the double-blinded placebo-controlled\n      portion, with all subjects receiving BIIB037."
        }, 
        "brief_title": "Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "detailed_description": {
            "textblock": "BIIB037 is an investigational product being developed as a disease modification treatment\n      for Alzheimer's disease (AD). BIIB037 is a fully human monoclonal antibody that recognizes\n      amyloid plaques. In animal models of Alzheimer's disease, treatment with BIIB037 was shown\n      to decrease beta amyloid content in animal brain. A single ascending dose study of BIIB037\n      in subjects with mild to moderate Alzheimer's Disease (AD) is ongoing. This study will be\n      conducted in subjects with prodromal or mild Alzheimer's Disease (AD) to assess the safety,\n      tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profile after multiple doses of\n      BIIB037."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must meet criteria for Prodromal Alzheimer's Disease (AD) or Mild\n             Alzheimer's Disease (AD):\n\n               1. Mini Mental State Examination (MMSE) score between 20-30,\n\n               2. Clinical Dementia Rating Scale (CDR) score of 0.5 or 1.0, and\n\n               3. a free recall score of lesser or equal to 27 on the Free and Cued Selective\n                  Reminding Test (FCSRT) for prodromal Alzheimer's Disease (AD).\n\n          -  Subjects must have a positive florbetapir positron emission tomography (PET) amyloid\n             scan.\n\n          -  Subjects must consent to apolipoprotein E (APOE) genotyping.\n\n          -  Apart from clinical diagnosis of Alzheimer's Disease (AD), subject must be in good\n             health.\n\n          -  Must have a reliable informant or caregiver.\n\n        Inclusion Criteria for the Long Term Extension (LTE), candidates must meet the following\n        eligibility criteria at Week 56:\n\n          1. Subject must have completed the placebo-controlled portion of the study. Subject must\n             have received 11 or more doses, and must not have missed more than 2 consecutive\n             doses; subjects who don't meet this criteria can only enter the Long Term Extension\n             (LTE) upon Sponsor's approval.\n\n          2. Mini Mental State Examination (MMSE) score >10 at the Week 54 visit.\n\n          3. Subject (or subject's legal representative) has the ability to understand the purpose\n             and risks of the study and provide signed and dated informed consent (or assent) and\n             authorization to use protected health information (PHI) in accordance with national\n             and local subject privacy regulations.\n\n          4. Must be ambulatory.\n\n        Exclusion Criteria:\n\n          -  Any medical or neurological condition (other than Alzheimer's Disease) that might be\n             a contributing cause of the subject's cognitive impairment.\n\n          -  Have had a stroke or Transient Ischemic Attack (TIA) or unexplained loss of\n             consciousness in the past 1 year.\n\n          -  Clinically significant psychatric illness in past 6 months.\n\n          -  Seizure in the past 3 years.\n\n          -  Poorly controlled diabetes mellitus.\n\n          -  History of unstable angina, myocardial infarction, chronic heart failure, or clinical\n             significant conduction abnormalities within 1 year prior to Screening.\n\n          -  Indication of impaired renal or liver function.\n\n          -  Have human immunodeficiency virus (HIV) infection.\n\n          -  Have a significant systematic illness or infection in past 30 days.\n\n          -  Brain MRI showing evidence of acute or sub-acute micro or macrohemorrhage, greater\n             than 4 microhemorrhages, cortical infarct or greater than one 1 lunar infarct.\n\n          -  Any contraindications to brain MRI or positron emission tomography (PET) scans.\n\n          -  Negative positron emission tomography (PET) scan with any amyloid-targeting ligand\n             within 48 weeks of Screening.\n\n          -  Clinically significant 12-lead electrocardiogram (ECG) abnormalities.\n\n          -  Alcohol or substance abuse in past 1 year.\n\n          -  Taking blood thinners (except for aspirin at a prophylactic dose or less)\n\n          -  Have changes in medications or doses of medication in past 4 weeks.\n\n        Exclusion Criteria for Long-term Extension:\n\n        Any medical or psychiatric contraindication or clinically significant abnormality that, in\n        opinion of the Investigator, will substantially  increase the risk associated with the\n        subject's participation in and completion of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01677572", 
            "org_study_id": "221AD103", 
            "secondary_id": "EUDRA CT #: 2012-000349-10"
        }, 
        "intervention": [
            {
                "arm_group_label": "BIIB037", 
                "description": "Subjects will recevie multiple doses of BIIB037 intravenous (IV) infusion", 
                "intervention_name": "BIIB037", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "intravenous (IV) infusion", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "September 12, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Delray Beach", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Myers", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hallendale Beach", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Eatontown", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toms River", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beechwood", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toledo", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease", 
        "overall_contact": {
            "email": "221AD103@biogenidec.com", 
            "last_name": "Medical Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety and tolerability as measured by adverse event monitoring and brain magnetic resonance imaging findings including the incidence of amyloid-related imaging abnormality-edema and amyloid-related imaging abnormality-hemorrhage.", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline to week 126"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01677572"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline as measured by 18F-AV-45 PET scan", 
                "safety_issue": "Yes", 
                "time_frame": "at week 26 and week 54"
            }, 
            {
                "measure": "Multiple dose pharmacokinetic (PK) serum concentrations of BIIB037", 
                "safety_issue": "Yes", 
                "time_frame": "up to week 52"
            }, 
            {
                "measure": "Immunogenecity of BIIB037 after multiple dose administration", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to week 70"
            }
        ], 
        "source": "Biogen Idec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}